Biotec Pharmacon ASA Reports Earnings Results for the Third Quarter Nine Months of 2013
For the nine months, the company reported sales revenues were NOK 16.8 million against NOK 15.4 million a year ago. LBITDA was NOK 15.2 million against NOK 16.2 million a year ago. Loss before tax was NOK 16.9 million against NOK 17.8 million a year ago. Cash flow used in operating activities was NOK 16.488 million against NOK 20.864 million a year ago. Cash flow used in operating activities was NOK 16.488 million against NOK 20.864 million a year ago.